These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Solid support synthesis of 6-aryl-2-substituted pyrimidin-4-yl phenols as anti-infective agents. Agarwal A; Srivastava K; Puri SK; Sinha S; Chauhan PM Bioorg Med Chem Lett; 2005 Nov; 15(22):4923-6. PubMed ID: 16169721 [TBL] [Abstract][Full Text] [Related]
26. Fragments: where are we now? Osborne J; Panova S; Rapti M; Urushima T; Jhoti H Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743 [TBL] [Abstract][Full Text] [Related]
27. Making space for anti-infective drug discovery. Nathan C Cell Host Microbe; 2011 May; 9(5):343-8. PubMed ID: 21575903 [TBL] [Abstract][Full Text] [Related]
29. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets. Li Q; Kang C Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623 [TBL] [Abstract][Full Text] [Related]
30. Natural products as starting points for future anti-malarial therapies: going back to our roots? Wells TN Malar J; 2011 Mar; 10 Suppl 1(Suppl 1):S3. PubMed ID: 21411014 [TBL] [Abstract][Full Text] [Related]
31. Detectives and helpers: Natural products as resources for chemical probes and compound libraries. Parthasarathy A; Mantravadi PK; Kalesh K Pharmacol Ther; 2020 Dec; 216():107688. PubMed ID: 32980442 [TBL] [Abstract][Full Text] [Related]
32. Thematic issue: TBD - new developments in the medicinal chemistry and drug discovery of agents for infectious diseases. Prakash O; Sharma PC Curr Top Med Chem; 2013 Aug; 13(16):1905-6. PubMed ID: 23895099 [No Abstract] [Full Text] [Related]
33. Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. Faïon L; Djaout K; Frita R; Pintiala C; Cantrelle FX; Moune M; Vandeputte A; Bourbiaux K; Piveteau C; Herledan A; Biela A; Leroux F; Kremer L; Blaise M; Tanina A; Wintjens R; Hanoulle X; Déprez B; Willand N; Baulard AR; Flipo M Eur J Med Chem; 2020 Aug; 200():112440. PubMed ID: 32505086 [TBL] [Abstract][Full Text] [Related]
34. A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery. Almela MJ; Lozano S; Lelièvre J; Colmenarejo G; Coterón JM; Rodrigues J; Gonzalez C; Herreros E PLoS One; 2015; 10(8):e0135139. PubMed ID: 26317851 [TBL] [Abstract][Full Text] [Related]
35. Drosophila melanogaster as a model host for the study of microbial pathogenicity and the discovery of novel antimicrobial compounds. Chamilos G; Samonis G; Kontoyiannis DP Curr Pharm Des; 2011; 17(13):1246-53. PubMed ID: 21470115 [TBL] [Abstract][Full Text] [Related]
36. CellFy: A Cell-Based Fragment Screen against C-Type Lectins. Schulze J; Baukmann H; Wawrzinek R; Fuchsberger FF; Specker E; Aretz J; Nazaré M; Rademacher C ACS Chem Biol; 2018 Dec; 13(12):3229-3235. PubMed ID: 30480432 [TBL] [Abstract][Full Text] [Related]
37. Recent progress in fragment-based lead discovery. Schulz MN; Hubbard RE Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685 [TBL] [Abstract][Full Text] [Related]
38. Anti-infectious drug repurposing using an integrated chemical genomics and structural systems biology approach. Ng C; Hauptman R; Zhang Y; Bourne PE; Xie L Pac Symp Biocomput; 2014; ():136-47. PubMed ID: 24297541 [TBL] [Abstract][Full Text] [Related]
39. IspC as target for antiinfective drug discovery: synthesis, enantiomeric separation, and structural biology of fosmidomycin thia isosters. Kunfermann A; Lienau C; Illarionov B; Held J; Gräwert T; Behrendt CT; Werner P; Hähn S; Eisenreich W; Riederer U; Mordmüller B; Bacher A; Fischer M; Groll M; Kurz T J Med Chem; 2013 Oct; 56(20):8151-62. PubMed ID: 24032981 [TBL] [Abstract][Full Text] [Related]
40. The SeeDs approach: integrating fragments into drug discovery. Hubbard RE; Davis B; Chen I; Drysdale MJ Curr Top Med Chem; 2007; 7(16):1568-81. PubMed ID: 17979768 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]